Company & Sponsor Intelligence
Hoffmann-La Roche
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials32
Recruiting6
Completed17
Countries7
Therapeutic footprint
alzheimersautismmultiple_sclerosisneuro_oncologyneurodevelopmental_otherneuromuscularparkinsonsschizophrenia
Indexed studies
NCT02901431A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD)
autism · United StatesPHASE2
autism · United StatesPHASE2
NCT03599245This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)
multiple_sclerosis · ArgentinaPHASE3
multiple_sclerosis · ArgentinaPHASE3
NCT04998812A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy
multiple_sclerosis · United StatesPHASE4
multiple_sclerosis · United StatesPHASE4
NCT03507569Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513
autism · United KingdomPHASE1
autism · United KingdomPHASE1
NCT05630066A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.
neurodevelopmental_other · United StatesPHASE2
neurodevelopmental_other · United StatesPHASE2
NCT05548556A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy
neuromuscular · United StatesPHASE2
neuromuscular · United StatesPHASE2
NCT04475848A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
autism · United KingdomPHASE1
autism · United KingdomPHASE1
NCT00884507A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
NCT00943826A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
neuro_oncology · United StatesPHASE3
neuro_oncology · United StatesPHASE3
NCT03593590Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis
multiple_sclerosis · AustriaCOMPLETED
multiple_sclerosis · AustriaCOMPLETED
NCT01192867A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
schizophrenia · United StatesPHASE3
schizophrenia · United StatesPHASE3
NCT04963270A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
neuromuscular · United StatesPHASE3
neuromuscular · United StatesPHASE3
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →